A&O advises on Exponent Private Equity’s refinancing of BBI Group and acquisition of Diarect AG
16 June 2020
Allen & Overy has advised Exponent Private Equity on the refinancing of the BBI Group and its acquisition of Diarect AG, a specialist in the development and production of recombinant and native antigens.
BBI Group is a leading B2B manufacturer and services provider to in vitro diagnostic healthcare, food safety and military bio-threat detection companies globally. Exponent originally invested in BBI Group in November 2015 and the recent refinancing and acquisition of Diarect AG further enhances BBI’s position as the world’s largest diagnostics components company with a market leading antigen portfolio.
The Allen & Overy team advising Exponent on the M&A aspects of this transaction was led by Frankfurt-based partner Michiel Huizinga with support from associates Laura Reuther and Maria Boerner and employment counsel Boris Blunck. The financing was led by London-based leveraged finance partner Neil Sinha with support from senior associates Adam Zecharia and James Green and associates Yasmin Joharchi and Chris Watkins.
For further information, please contact Ben Davies, email@example.com on +44 (0)20 3088 1955.